For the quarter ending 2025-09-30, VTRS has $37,920,400K in assets. $22,702,800K in debts. $975,300K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | 975,300 | 566,400 | 755,000 | 734,800 |
| Accounts receivable, net | 3,371,600 | 3,258,100 | 3,125,700 | 3,221,300 |
| Inventories | 4,111,400 | 4,264,300 | 4,096,400 | 3,854,100 |
| Prepaid expenses | 186,100 | 179,900 | 170,500 | 140,900 |
| Deferred consideration due from biocon biologics-Biocon Biologics-Other Current Assets | - | - | - | 0 |
| Available-for-sale fixed income securities | - | - | - | 38,000 |
| Available-for-sale securities-Debt Securities | 40,400 | 39,700 | 39,000 | - |
| Fair value of financial instruments | 77,400 | 142,400 | 152,700 | 261,600 |
| Equity securities | 64,000 | 60,100 | 55,500 | 55,500 |
| Deferred charge for taxes on intercompany profit | 658,400 | 665,100 | 610,100 | 526,600 |
| Income tax receivable | 215,600 | 339,200 | 262,800 | 300,700 |
| Other current assets | 251,200 | 259,400 | 354,700 | 387,200 |
| Prepaid expenses and other current assets | 1,493,100 | 1,685,800 | 1,645,300 | 1,710,500 |
| Assets held for sale | - | - | - | 0 |
| Total current assets | 9,951,400 | 9,774,600 | 9,622,400 | 9,520,700 |
| Property, plant and equipment, gross | 5,106,500 | 5,067,200 | 4,939,700 | 4,869,300 |
| Accumulated depreciation | 2,480,300 | 2,424,600 | 2,304,100 | 2,203,200 |
| Property, plant and equipment, net | 2,626,200 | 2,642,600 | 2,635,600 | 2,666,100 |
| Finite-lived intangible assets, original cost | 34,810,200 | 34,906,300 | 33,905,000 | 33,348,500 |
| In-process research and development | 777,800 | 801,900 | 804,400 | 814,200 |
| Intangible assets, gross, excluding goodwill | 35,588,000 | 35,708,200 | 34,709,400 | 34,162,700 |
| Finite-lived intangible assets, accumulated amortization | 19,865,100 | 19,384,400 | 18,047,100 | 17,091,800 |
| Intangible assets, net | 15,722,900 | 16,323,800 | 16,662,300 | 17,070,900 |
| Goodwill | 6,730,800 | 6,748,300 | 6,462,100 | 9,133,300 |
| Deferred income tax benefit | 999,000 | 924,300 | 817,600 | 753,000 |
| Other assets | 1,890,100 | 1,997,900 | 2,274,900 | 2,356,900 |
| Total assets | 37,920,400 | 38,411,500 | 38,474,900 | 41,500,900 |
| Accounts payable | 1,793,400 | 1,782,600 | 1,988,400 | 1,853,700 |
| Income taxes payable | 0 | 0 | 93,400 | 192,700 |
| Current portion of long-term debt and other long-term obligations | 1,951,900 | 1,680,700 | 8,500 | 8,300 |
| Liabilities held for sale | - | - | - | 0 |
| Other current liabilities | 3,618,800 | 3,670,100 | 3,629,800 | 3,724,700 |
| Total current liabilities | 7,364,100 | 7,133,400 | 5,720,100 | 5,779,400 |
| Long-term debt | 12,487,600 | 12,791,600 | 14,177,500 | 14,038,900 |
| Deferred income tax liability | 1,028,200 | 1,080,800 | 1,082,500 | 1,107,900 |
| Other long-term obligations | 1,822,900 | 1,835,200 | 1,844,400 | 1,939,200 |
| Total liabilities | 22,702,800 | 22,841,000 | 22,824,500 | 22,865,400 |
| Common stock 0.01 par value, 3,000,000,000 shares authorized shares issued 1,245,284,268 and 1,234,131,491 as of september30, 2025 and december31, 2024 | 12,500 | 12,500 | 12,400 | 12,300 |
| Additional paid-in capital | 18,890,700 | 18,998,200 | 18,960,800 | 18,921,600 |
| Retained earnings | -48,200 | 80,000 | 227,900 | 3,418,800 |
| Accumulated other comprehensive loss | -2,713,200 | -2,664,400 | -2,870,900 | -3,212,900 |
| Total viatris inc. equity, before treasury stock | 16,141,800 | 16,426,300 | 16,330,200 | 19,139,800 |
| Less treasury stock at cost | 924,200 | 855,800 | 679,800 | 504,300 |
| Total equity | 15,217,600 | 15,570,500 | 15,650,400 | 18,635,500 |
| Total liabilities and equity | 37,920,400 | 38,411,500 | 38,474,900 | 41,500,900 |
Viatris Inc (VTRS)
Viatris Inc (VTRS)